Anne E. Zepeski
This is a small, pilot study with a primary goal of assessing patient perceptions of two medication treatments for supraventricular tachycardia in adult patients treated in the Emergency Department.
Inclusion Criteria: 1. Adult patients (18 years and older) 2. Diagnosis of acute, stable SVT in the emergency department Exclusion Criteria: 1. Receipt of IV AV-nodal blocking agents prior to study enrollment (includes adenosine, non-dihydropyridine calcium channel blockers, beta-antagonists in pre-hospital and/or hospital setting). 2. Reported or confirmed personal history of Wolff-Parkinson-White (WPW) syndrome 3. History of heart failure with reduce ejection fraction (HFrEF) (LVEF\</= 40%) 4. Severe bronchoconstrictive lung disease 5. Prior hypersensitivity to study medication 6. Previou…
IV adenosine at standard doses for SVT (6 mg, 12 mg)
IV diltiazem at standard doses for SVT (0.25 mg/kg)
Arctuva estimate
Verify or correct the compensation shown for this listing.